NEW YORK, NY--(Marketwired - Oct 3, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) has several clinical trials already underway, and a host of others scheduled to commence in the company months as the company feverishly prepares products for market in its transition from solely a research and development firm to a biotech with products in the marketplace. Plandaí has stated its goal is to have most of the trials it has commissioned completed by the end of March 2014 -- which will serve to bolster sales efforts as customers are educated about the advantages of improved bioavailability.
All of these trials are crucial to the company getting its products in the marketplace, and commencing in January 2014, Plandaí says it should be producing Phytofare™ Catechin Complex at its Senteeko facility in South Africa. According to the company, some of the product will be shipped to a Pheroid™ production facility in South Africa for further processing. The Phytofare™/Pheroid™ products are currently being tested to ensure conformity to the company's standard profile, before being released to market.
Company executives have estimated that its products will be ready to ship to customers in four different formulations after the clinical trials have been completed in March 2014. Those formulations include; Phytofare™ Catechin Complex, a water-soluble powder, Ph2™ Topical Catechin Complex, a topical cream that has Phytofare™ nano-entrapped in Pheroid™, Ph2™ Oral Catechin Complex, a gel tab version of Phytofare™ nano-entrapped in Pheroid™, suitable for oral consumption, and Ph2™ Liquid Catechin Complex, an oral version of Phytofare™ nano-entrapped in Pheroid™ in a liquid suspension, suitable for mixing into beverages and liquid medications.
The success of each of these formulations in the marketplace is somewhat contingent upon successful clinical trials, though it is impossible to anticipate all potential applications. Plandaí seems determined to focus first on trials that demonstrate the overall effectiveness of the various products in broad areas. In August, Plandaí started two clinical trials.
Continue Reading: www.stockmarketmediagroup.com/features
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, CEO Interviews and Feature Articles. For more information: www.stockmarketmediagroup.com